Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 170 Neoplasm Metastasis 13 Prostatic Neoplasms, Castration-Resistant 11 Metastatic Castration-resistant Prostate Cancer 7 Neoplasms 6 Metastatic Castration Resistant Prostate Cancer 6 Breast Neoplasms 6 Prostate Cancer Metastatic 4 Metastatic Castration-Resistant Prostate Cancer 4 Urogenital Neoplasms 3 Genital Neoplasms, Male 3 Prostatic Diseases 2 Neoplasms by Site 2 Metastatic Castration-resistant Prostate Cancer (mCRPC) 2 Genital Diseases, Male 2 Castration-resistant Prostate Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Adenocarcinoma 2 Urinary Bladder Neoplasms 1 Stage II Prostate Adenocarcinoma 1 Sleep Initiation and Maintenance Disorders 1 Salivary Glands Tumors 1 Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone 1 Prostate Adenocarcinoma 1 Pharmacogenetic Study 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Neoplasms 1 Oligometastatic Prostate Carcinoma 1 Newly Diagnosed Oligometastatic Prostate Cancer 1 Neoadjuvant Therapy 1

Interventions

Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pharmacogenetic Study × Abiraterone Acetate × Clear all

NCT01858441 2020-12-04

ABIGENE

Centre Antoine Lacassagne

Phase NA Completed

Pharmacogenetic Study

Data powered by HemOnc (CC BY 4.0) Colophon ⚡